TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06447740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dopamine
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status

Intervention type: DRUG
Group type: OTHER
Intervention: Dopamine
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Fractional Flow Reserve, Renal
Description: Renal FFR will be measured based on SOP

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fractional Flow Reserve, Renal
Description: Renal FFR will be measured based on SOP

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve, Renal
Description: Renal FFR will be measured based on SOP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal artery stenting
Description: Renal artery stenting will be implanted based on the protocol
Study: NCT06487585

Intervention type: DRUG
Group type: OTHER
Intervention: Angiotensin II
Description: Angiotensin II: Starting dose of 20 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
Study: NCT05921617

Intervention type: OTHER
Intervention: No intervention
Description: Routine care
Study: NCT04455828

Intervention type: DEVICE
Intervention: WHOOP strap 3.0
Description: WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.

Intervention type: DEVICE
Intervention: WHOOP strap 3.0
Description: WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
Study: NCT05067205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release surgery
Description: Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Carpal tunnel release surgery
Description: Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively
Study: NCT04963283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
Study: NCT05269823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice-therapy
Description: Ice therapy will be provided prior to intravitreal injection provision

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Ice-therapy
Description: No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision
Study: NCT05856071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: goniometer
Description: to measure the range of motion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: goniometer
Description: to measure the range of motion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clamshells exercises
Description: clamshells exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy
Description: traditional physical therapy
Study: NCT05025410

Intervention type: DRUG
Intervention: Remimazolam
Description: Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
Study: NCT04973995

Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury

Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury

Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury

Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury

Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury

Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury

Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury

Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
Study: NCT04694118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rebound therapy
Description: 3 days a week in 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rebound therapy
Description: 3 days a week in 12 weeks
Study: NCT05438810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c,Fulvestrant,Goserelin acetate
Description: FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,Fulvestrant,Goserelin acetate
Description: Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
Study: NCT02437552

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ergometer cycle exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine physiotherapy
Description: routine physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine physiotherapy
Description: routine physiotherapy
Study: NCT04920539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Delta-9-THC
Description: Active Delta-9-THC (0.03 mg/kg) administered intravenously.
Study: NCT04995900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community education
Description: Heart Matters coordinators will deliver heart health education to the community using HM materials and Partner resources.
Study: NCT04403854

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: If possible with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: If possible with spectroscopy

Intervention type: PROCEDURE
Intervention: Spinal Tap
Description: together with CSF pressure estimate
Study: NCT05177172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High beta glucans
Description: higher dose betaglucans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low beta glucans
Description: lower dose beta glucans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low beta glucans + low polar lipids
Description: low dose betaglucans in a combination with low dose of polar lipids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polar lipids
Description: low dose polar lipids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No beta glucans or polar lipids
Study: NCT05035342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) capsules
Description: Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules.
Study: NCT06123442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Resilience Intervention
Description: Participants will have 12 weeks to complete the program, and then before the post-assessment, there will be a one-month feedback period \[22\]. This includes twelve components: 1) preliminary routine, 2) significance of knowing yourself, 3) interpreting events and stressors, 4) taking autonomy over events, 5) practicing mindfulness and self-compassion, 6) learning adaptation skills, 7) building connection , 8) purpose in life and personal growth, 9) Regulation and disclosure of emotions, 10) practicing gratitude, and 11) positive Communication both intra and interpersonal, 12) overcoming obstacles and moving forward (in the context of current problems) and the conclusion/retrospection are addressed in 12 sessions while closure and post assessment will be done after a month
Study: NCT05921513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft Procedure
Description: This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Free Gingival Graft Procedure
Description: This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft Procedure
Description: This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.
Study: NCT05534737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAICP + usual care of social services
Description: The intervention consists of applying a MAICP from the municipal social services involved for 2 years (summer 2022-summer 2024). To this end, the AICP.com project will sign the necessary institutional agreements to contract and integrate, in the municipal Social Services of each territory, an intervention team that will work with them in a coordinated manner, although its specific task is the implementation of the MAICP during the intervention period of the project and the baseline, intermediate and final evaluations of the effectiveness of this model in the study population.
Study: NCT05966675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conduction system pacing
Description: Implantation of cardiac implantable electronic device (CIED) with conduction system pacing (left bundle branch area pacing or his bundle pacing).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: right ventricular or biventricular pacing
Description: Implantation of cardiac implantable electronic device with right ventricular or biventricular pacing according to left ventricular ejection fraction and current ESC guidelines.
Study: NCT06498115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
Study: NCT05590247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting Diet
Description: Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
Study: NCT04891913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007/ Placebo 15mg
Description: 15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007/ Placebo 30mg
Description: 30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007/ Placebo 60mg
Description: 60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Study: NCT05186935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injectable Hydrogel treatment
Description: The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
Study: NCT06079034

Intervention type: PROCEDURE
Intervention: Venovenous ECMO
Description: Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy

Intervention type: PROCEDURE
Intervention: Venoarterial ECMO
Description: Initial support type of venoarterial ECMO
Study: NCT05785130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: background noise
Description: Using sound machine for 3 days at bedtime for 7 hours(11p.m.- 6a.m.) in a decibel of 40-50.
Study: NCT06418685

Intervention type: DEVICE
Intervention: Treatment with Vibrating Capsule
Description: Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation.
Study: NCT05518084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liponovo tissue product
Description: Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Liponovo tissue product
Description: Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
Study: NCT00107549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])
Description: Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
Description: Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
Study: NCT05899270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D reconstruction automatic matching system
Description: it is an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.
Study: NCT05770505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training using an e-health tool
Description: Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Personal Activity Intelligence (PAI) equivalents per week Control: No follow-up
Study: NCT05899270

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional method for selecting double lumen tube
Description: In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
Study: NCT04969718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEADS Plus educational posters
Description: This intervention covers depression and its symptoms, the link between depression and suicide, the risk and protective factors associated with suicide, the warning signs of suicide, seeking help and overcoming barriers to seeking help, and school and community suicide prevention resources. Six educational posters will also be displayed in class rooms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Question, Persuade, and Refer (Teachers) Plus educational posters
Description: It is a manualised programme for gatekeepers, originally developed in the USA which to train teachers/school staff to identify the suicide risk in students and encourage students at risk of suicide to seek professional help. Six educational posters will also be displayed in classrooms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening by Professionals programme plus educational posters
Description: This is an indicated or selective intervention which is based on students' responses to the baseline questionnaires. Participating health professionals review students' responses to the questionnaires used in the study and students whose scores meet pre-established cutoff points will be invited to participate in a professional mental health clinical assessment and if needed, referred to clinical services. Six educational posters will also be displayed in classrooms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational posters
Description: Six educational posters will be displayed in all schools in this cluster.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational posters
Description: Six educational posters will be displayed in all schools in this cluster.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational posters
Description: Six educational posters will be displayed in all schools in this cluster.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational posters
Description: Six educational posters will be displayed in all schools in this cluster.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational posters
Description: Six educational posters will be displayed in all schools in this cluster.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Question, Persuade, and Refer (Parents) Plus educational posters
Description: It is a manualised programme for gatekeepers (parents), originally developed in the USA which to train parents to support the young people at risk of suicide. Six educational posters will also be displayed in classrooms.